Gabapentin
Brand names: Gabapentin, gabapentin, GABAPENTIN, Neurontin, Gralise, RELGAABI, GABARONE, Gaba 300-EZS
Warnings
Major Warnings: - Suicidal Behavior: AEDs including gabapentin approximately double the risk of suicidal thoughts/behavior, affecting about 1 in 500 patients. Early warning signs require immediate healthcare provider notification. - Pediatric Neuropsychiatric Effects: In children 3-12 years, gabapentin causes emotional lability (6%), hostility (5.2%), hyperkinesia (4.7%), and thought disorder (1.7%). - Withdrawal Risk: Abrupt discontinuation can cause severe seizures. Gradual tapering over minimum 1 week is required. - Hypersensitivity Reaction: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported, presenting with fever, rash, and lymphadenopathy. ---
Contraindications
4 CONTRAINDICATIONS Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. Known hypersensitivity to gabapentin or its ingredients ( 4 )
Overdose
10 OVERDOSAGE Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, sedation, hypoactivity, or excitation. Acute oral overdoses of gabapentin have been reported. Symptoms have included double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea. Fatal respiratory depression has been reported with gabapentin overdose, alone and in combination with other CNS depressants. Gabapentin can be removed by hemodialysis. If overexposure occurs, call your poison control center at 1-800-222-1222.
Drug interactions
7 DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment ( 5.4 , 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [ see Warnings and Precautions (5.7) ] . Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure [ see Clinical Pharmacology (12.3) ]. The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone. Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression [see Clinical Pharmacology (12.3) ]. 7.2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs [ see Clinical Pharmacology (12.3) ] . 7.3 Maalox ® (aluminum hydroxide, magnesium hydroxide) The mean bioavailability of gabapentin was reduced by about 20% with concomitant use of an antacid (Maalox ® ) containing magnesium and aluminum hydroxides. It is recommended that gabapentin be taken at least 2 hours following Maalox administration [see Clinical Pharmacology (12.3) ]. 7.4 Drug/Laboratory Test Interactions Because false positive readings were reported with the Ames N-Multistix SG ® dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein.
Uses
Gabapentin treats two main conditions: Postherpetic Neuralgia: "Gabapentin is indicated for the management of postherpetic neuralgia in adults." Epilepsy: The medication serves as "adjunctive therapy in the treatment of partial seizures" in patients over 12 years and in pediatric patients ages 3-12 years. ---
Dosage forms & strengths
All identified pills
R 204
WHITE OVAL · Gabapentin
R 637
GRAY OVAL · Gabapentin
8 manufacturers
R 636
GREEN BULLET · Gabapentin
R2665
WHITE;BROWN CAPSULE · Gabapentin
2 manufacturers
R2666
YELLOW;BROWN CAPSULE · Gabapentin
8 manufacturers
R2666
BROWN;YELLOW CAPSULE · Gabapentin
4 manufacturers
R2667
ORANGE;BROWN CAPSULE · Gabapentin
R665
BROWN;WHITE CAPSULE · Gabapentin
4 manufacturers
R665
WHITE;BROWN CAPSULE · Gabapentin
5 manufacturers
R667
ORANGE;BROWN CAPSULE · Gabapentin
7 manufacturers
R667
BROWN;ORANGE CAPSULE · Gabapentin
5 manufacturers
RX 629
ORANGE CAPSULE · Gabapentin
RX 627
WHITE CAPSULE · Gabapentin
RX 628
WHITE CAPSULE · Gabapentin
S617 100MG
WHITE CAPSULE · Gabapentin
2 manufacturers
S618 300MG
YELLOW CAPSULE · Gabapentin
2 manufacturers
S619 400MG
ORANGE CAPSULE · Gabapentin
SG 181
ORANGE CAPSULE · Gabapentin
7 manufacturers
SG 179
WHITE CAPSULE · Gabapentin
20 manufacturers
SG 180
WHITE CAPSULE · Gabapentin
8 manufacturers
SG 181
WHITE CAPSULE · Gabapentin
6 manufacturers
SG 177
WHITE CAPSULE · Gabapentin
12 manufacturers
SG 178
WHITE CAPSULE · Gabapentin
19 manufacturers
SG 180
YELLOW CAPSULE · Gabapentin
14 manufacturers
SLV 300
WHITE OVAL · Gabapentin
2 manufacturers
SLV 600
BROWN OVAL · Gabapentin
4 manufacturers
WW 990
WHITE OVAL · Gabapentin
WW 991
WHITE OVAL · Gabapentin
West ward
ORANGE CAPSULE · Gabapentin
Westward 994
ORANGE CAPSULE · Gabapentin
Westward 993
YELLOW CAPSULE · Gabapentin
3 manufacturers
Westward 991
GRAY CAPSULE · Gabapentin
3 manufacturers
ZE 72
WHITE OVAL · Gabapentin
ZE71
WHITE OVAL · Gabapentin
8 manufacturers
ZE72
WHITE OVAL · Gabapentin
8 manufacturers
ORANGE CAPSULE · Gabapentin
YELLOW CAPSULE · Gabapentin
GRAY CAPSULE · Gabapentin
Side effects
Postherpetic Neuralgia patients: - Dizziness (28%) - Somnolence (21.4%) - Peripheral edema (8.3%) - Diarrhea (5.7%) Epilepsy patients >12 years: - Somnolence (19.3%) - Dizziness (17.1%) - Ataxia (12.5%) - Fatigue (11%) ---